HUTCHMED Licenses KRAS-EGFR Cancer Therapy to GSK in $1.295B Deal
Event summary
- HUTCHMED licenses HMPL-A830, a KRAS-EGFR antibody-targeted therapy conjugate, to GSK for $110M upfront and up to $1.295B in milestones.
- GSK gains worldwide rights excluding Mainland China, Hong Kong, Macau, and Taiwan for colorectal, pancreatic, and lung cancer indications.
- HUTCHMED will lead global Phase I trials starting in H2 2026, with GSK handling subsequent development and commercialization.
- HMPL-A830 is the first drug from HUTCHMED’s ATTC platform to be licensed to a global partner.
The big picture
This deal underscores the growing strategic importance of antibody-targeted therapy conjugates in precision oncology, particularly for KRAS-altered tumors. HUTCHMED’s collaboration with GSK validates its ATTC platform and positions it as a key player in the biopharma innovation ecosystem. The $1.295B potential deal size highlights the high stakes in developing next-generation cancer therapies.
What we're watching
- Clinical Progress
- The pace at which HMPL-A830 advances through Phase I trials and demonstrates efficacy in colorectal, pancreatic, and lung cancer.
- Commercial Potential
- Whether GSK can successfully commercialize HMPL-A830 outside China, given the competitive landscape in oncology.
- Pipeline Expansion
- How HUTCHMED leverages this deal to advance its ATTC platform and secure additional partnerships for earlier-stage candidates.
Related topics